Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

High-dose melphalan (HDM) with peripheral blood stem cell transplant (PBSCT) is a common treatment for patients with multiple myeloma (MM) and more recently also with AL amyloidosis (ALA). We report two female patients with severe renal failure who underwent treatment with HDM for MM (patient 1) and ALA (patient 2). Both patients developed severe encephalopathy with generalised tonic-clonic seizures and a Glasgow Coma Scale (GCS) of 3/15. Causes for coma such as infections, metabolic disturbances, cerebral ischaemia or haemorrhage were excluded. Patient 1 died on day 25 post transplant while comatose. Patient 2 recovered from her comatose state 18 days after transplantation. To our knowledge this is the first report on a possible role of high-dose melphalan in the development of encephalopathy.

Original publication

DOI

10.1038/sj.bmt.1702041

Type

Journal article

Journal

Bone Marrow Transplant

Publication Date

11/1999

Volume

24

Pages

1141 - 1143

Keywords

Amyloidosis, Antineoplastic Agents, Alkylating, Coma, Combined Modality Therapy, Epilepsy, Tonic-Clonic, Fatal Outcome, Female, Glasgow Coma Scale, Hematopoietic Stem Cell Transplantation, Humans, Melphalan, Middle Aged, Multiple Myeloma, Treatment Outcome